Hematologic cancers & cell therapy
Verified cellular immunotherapy (CAR-T) and complex allogeneic hematopoietic transplantation pathways for relapsed or refractory hematologic malignancies in top Chinese tertiary centers.
Leading Hospital Centers & Specific Treatments Offered
Research notes on Chinese tertiary hospitals, specific advanced modalities, target indications, and international patient pathways
- Ruijin Hospitalnot in our hospital directory
- Shanghai SinoUnited Hospitalnot in our hospital directory
- Peking Union Medical College Hospitalnot in our hospital directory
- Shanghai Jiahui International Hospitalnot in our hospital directory
A missing entry means our hospital directory does not cover that facility yet; it is not a statement about the facility's clinical capability.
Ruijin Hospital (上海交通大学医学院附属瑞金医院)
BCMA CAR-T Therapy (Equecabtagene Autoleucel / 伊基奥仑赛)
Relapsed or refractory multiple myeloma (≥3 prior lines)
Clinical Feature: NMPA approved commercial product, 96% overall response rate, full-trajectory CRS/ICANS ICU monitoring.
CD19 CAR-T Therapy (Relma-cel / 瑞基奥仑赛 & Axi-cel / 阿基仑赛)
Relapsed/refractory large B-cell lymphoma (DLBCL) & follicular lymphoma
Clinical Feature: Designated infusion center with standardized leukapheresis, bridging chemotherapy, and long-term follow-up.
Haploidentical & Matched Allogeneic Stem Cell Transplant (Allo-HSCT)
High-risk acute myeloid leukemia (AML) & acute lymphoblastic leukemia (ALL)
Clinical Feature: Advanced sterile laminar flow transplant ward cluster with specialized GVHD prevention and control protocols.
Verified international medical department (VIP Clinic) supporting English medical records review, case coordinator, and hospital deposit procedures.
Direct medical intake available. Requires pre-travel submission of complete pathology slides, bone marrow flow cytometry, and prior regimen logs.
Shanghai Jiahui International Hospital (上海嘉会国际医院)
Commercial CAR-T Infusion Fast-Track (Yescarta / Axicabtagene Ciloleucel)
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Clinical Feature: Dedicated international inpatient floor, full-time English-speaking hematologists, overseas medical visa invitation letters.
Autologous Stem Cell Transplantation (Auto-HSCT)
High-dose consolidation for multiple myeloma and sensitive lymphomas
Clinical Feature: Class-100 clean ward environment with comprehensive supportive care and cross-border continuity planning.
Publicly verified direct international office (+852 4619 1904 / internationaloffice@jiahui.com) with remote multidisciplinary tumor board review.
Active intake for international patients. Provides itemized formal medical quotes and medical visa assistance.
Peking Union Medical College Hospital (北京协和医院)
Precision Targeted & Multi-Agent Immunotherapy Regimens
Castleman disease, primary CNS lymphoma, refractory plasma cell disorders
Clinical Feature: National Rare Diseases Diagnosis and Treatment Network lead institution; comprehensive multidisciplinary diagnosis (MDT).
Ultra-Sensitive Minimal Residual Disease (MRD) Clearance Protocols
Acute leukemias and residual disease eradication planning
Clinical Feature: High-dimensional 10-color flow cytometry and high-throughput NGS deep clonal tracking.
English-speaking International Medical Services (IMS) provides outpatient appointments, inpatient care, and remote second opinions.
Intake through International Medical Services. High case-complexity threshold; requires comprehensive prior diagnostics in English.
Shanghai SinoUnited Hospital (上海非公立国际中心 - 联动公立三甲)
Pre-CAR-T Evaluation & Public-Private Bidirectional Referral
International patients seeking cell therapy candidacy assessment in China
Clinical Feature: Bilingual oncologist first-opinion, digital DICOM / pathology forwarding to tertiary hospital professors.
Direct international concierge (+86 400 186 2116 / internationalcare@suh.cn) providing multilingual communication.
Recommended as an international screening entry point for patients needing translation and liaison with public hospital specialists.
Target Disease Indications & Qualified Hospital Finder (6)
Which Chinese tertiary hospitals are noted for the beds, ICU support, and technologies each condition typically needs
Relapsed or Refractory Multiple Myeloma (复发/难治多发性骨髓瘤)
Target Stage & Goal: For patients with multiple myeloma who have progressed after ≥3 lines of prior therapy (including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody). Goal: Deep MRD-negative molecular remission.
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (上海交通大学医学院附属瑞金医院)
Shanghai · Grade 3A Public (National Medical Center for Metabolic & Hematologic Diseases)Class-10,000 sterile laminar-flow transplant wards (35+ beds), specialized leukapheresis lab, 24/7 dedicated Hematology ICU for rapid CRS/ICANS emergency rescue, national GMP-grade cell preparation qualification.
Equecabtagene Autoleucel (伊基奥仑赛 BCMA CAR-T, Fucaso) & Autologous Stem Cell Rescue.
Diagnosed RRMM after ≥3 prior lines; ECOG 0-1; absolute lymphocyte count ≥0.5×10^9/L; CrCl ≥40 mL/min; LVEF ≥45%; no active uncontrolled systemic infection.
Peking Union Medical College Hospital (北京协和医院)
Beijing · Grade 3A Public (National Center for Difficult & Complicated Diseases)National Rare Diseases Diagnosis and Treatment Network Lead Center, specialized plasma-cell disorder MDT board, high-resolution immunofixation and mass spectrometry laboratories.
Novel dual-target BCMA/CD19 sequential CAR-T protocols & salvage alkylator-free bridging regimens.
Documented extramedullary relapse, high-risk cytogenetics (del(17p), t(4;14), 1q21 amp); adequate bone marrow cellularity for apheresis.
Relapsed or Refractory Diffuse Large B-cell Lymphoma (复发/难治弥漫大B细胞淋巴瘤)
Target Stage & Goal: Aggressive CD19+ B-cell lymphoma refractory to first-line R-CHOP or relapsed within 12 months post-autologous stem cell transplantation.
Ruijin Hospital (上海瑞金医院)
Shanghai · Grade 3A Public (National Hematology Reference Center)Designated commercial infusion center for both Axi-cel and Relma-cel; full-process electronic tracking from vein-to-vein; dedicated cellular therapy clinical coordinator.
Relmacabtagene Autoleucel (瑞基奥仑赛 Carteyva) & Axicabtagene Ciloleucel (阿基仑赛 Yescarta).
Histologically verified CD19+ DLBCL, primary refractory or progressed after ≥2 lines of systemic chemoimmunotherapy; ECOG 0-1.
Shanghai Jiahui International Hospital (上海嘉会国际医院)
Shanghai · JCI-Accredited International Hospital (Strategic Collaboration with Massachusetts General Hospital Cancer Center)Full-time bilingual oncologists and hematologists, dedicated single-patient HEPA-filtered cell therapy inpatient floor, direct international commercial insurance direct billing, overseas medical visa invitation support.
Commercial CD19 CAR-T Infusion Fast-Track & Autologous Stem Cell Mobilization.
Overseas or bilingual patients with CD19+ high-grade B-cell lymphoma; stable cardiopulmonary function; manageable tumor burden suitable for fludarabine/cyclophosphamide lymphodepletion.
Acute Lymphoblastic Leukemia in Relapse (复发/难治急性淋巴细胞白血病)
Target Stage & Goal: B-cell acute lymphoblastic leukemia (B-ALL) with morphologic relapse or persistent minimal residual disease (MRD+ ≥0.01%) post-consolidation.
Ruijin Hospital & Shanghai Children's Medical Center (SCMC)
Shanghai · National Children's Medical Center & National Hematology CenterUltra-sensitive 10-color flow cytometry minimal residual disease (MRD) detection lab (sensitivity 10^-5), Class-100 sterile isolation transplant rooms, bridging haploidentical transplantation pipeline.
CD19 / CD22 targeted CAR-T cell infusion followed by consolidative allogeneic hematopoietic stem cell transplantation (Allo-HSCT).
Relapsed/refractory B-cell ALL; bone marrow blast count <30% before lymphodepletion; adequate organ reserve; no severe active GVHD.
Acute Myeloid Leukemia & High-Risk MDS (急性髓系白血病与高危MDS)
Target Stage & Goal: Unfavorable-risk cytogenetic/molecular AML (FLT3-ITD, TP53, complex karyotype) or induction failure requiring targeted therapy and immediate transplantation.
Ruijin Hospital (上海交通大学医学院附属瑞金医院)
Shanghai · Grade 3A Public (State Key Laboratory of Medical Genomics)NGS-based comprehensive 100+ gene myeloid mutation profiling (FLT3-ITD/TKD, NPM1, IDH1/2, TP53), Asia's largest haploidentical transplant database.
Precision targeted regimens (Venetoclax + Azacitidine, Gilteritinib) combined with haploidentical or matched unrelated Allo-HSCT.
High-risk cytogenetic/molecular AML or induction failure; patient age <70; HCT-CI ≤3; documented absence of active fungal infection.
Complex Allogeneic Hematopoietic Stem Cell Transplantation (复杂异基因造血干细胞移植)
Target Stage & Goal: Severe hematologic diseases requiring allogeneic stem cell reconstitution with haploidentical family donors or cord blood bridging.
Ruijin Hospital & Peking Union Medical College Hospital
Shanghai / Beijing · Grade 3A Public (National Medical Centers)50+ continuous positive-pressure HEPA laminar airflow transplant rooms, specialized post-transplant infection isolation unit, advanced extracorporeal photopheresis (ECP) for refractory GVHD.
Modified Beijing Protocol Haploidentical Transplantation, matched unrelated donor (MUD) transplant, and cord blood salvage transplantation.
High-risk hematologic malignancy in complete remission; HLA-typing completed for patient and potential family donors; negative viral screen for active hepatitis/HIV.
Target-Specific Solid Tumor CAR-T (CLDN18.2 Advanced Gastric / GEJ Adenocarcinoma)
Target Stage & Goal: Metastatic gastric or gastroesophageal junction adenocarcinoma with confirmed CLDN18.2 overexpression after failure of standard chemotherapy.
Shanghai Jiahui International Hospital & Ruijin Hospital
Shanghai · JCI International Hospital & National Public CenterStandardized IHC 28-8 CLDN18.2 pathology testing lab, dedicated gastrointestinal oncology multidisciplinary team, intensive monitoring protocol for delayed mucosal and systemic toxicities.
Satricabtagene Autoleucel (CT041 / CLDN18.2-targeted CAR-T) under strict clinical pathway.
Histologically confirmed advanced gastric/GEJ adenocarcinoma; positive CLDN18.2 expression (≥2+ in ≥40% cells); failed ≥2 prior lines; no bowel obstruction or massive ascites.
Records Needed Before Clinical Review (7)
- ✓Original pathology paraffin blocks or high-resolution digital slide scans
- ✓Bone marrow biopsy morphology, 10-color flow cytometry, cytogenetic FISH, and NGS panel reports
- ✓Chronological log of all prior lines: drug regimens, exact dosages, duration, best response, and resistance reasons
- ✓Whole-body PET-CT or contrast CT/MRI within the last 30 days (original DICOM disc files)
- ✓Organ baseline reserve: Complete blood count, liver/renal panel, coagulation, cardiac echocardiogram (LVEF), and pulmonary PFT
- ✓Infectious disease screen: Quantitative HBV DNA, HCV RNA, HIV, CMV, and EBV PCR titers
- ✓Performance status documentation: ECOG score and home-country hematologist referral letter
Practical Pathway Financial Scope (4 stages)
Where expenses occur across the pathway · figures are published reference rangesScope: Comprehensive multidisciplinary tumor board review, bone marrow flow cytometry/MRD re-testing, baseline organ workup, leukapheresis machine run, and outpatient bridging medication.
Financial Notes: Typically self-funded deposit or covered by international private health insurance; varies if bridging chemotherapy is needed.
Scope: Commercial CAR-T pharmaceutical purchase (e.g. Equecabtagene Autoleucel / Relmacabtagene Autoleucel) or trial-protocol cell laboratory production.
Financial Notes: Fixed commercial manufacturer price in China (approx. 990,000 - 1,200,000 RMB for commercial products); separate from hospital clinical services.
Published reference range · noted 2026-08-18 · confirm current price
Scope: Flu/Cy lymphodepleting chemotherapy, sterile laminar ward stay (typically 14-21 days), daily IL-6/cytokine tracking, tocilizumab/steroid CRS intervention, and potential ICU escalation.
Financial Notes: Variable depending on the severity of Cytokine Release Syndrome (CRS) or neurotoxicity (ICANS); patients must reserve an ICU safety buffer.
Scope: Day-30 and Day-90 bone marrow and PET-CT evaluations, immunoglobulin replacement infusions, antiviral prophylaxis, and formal English discharge summary translation.
Financial Notes: Outpatient visits and imaging; long-term infection monitoring transitions to the patient's home-country hematologist.
Published reference ranges noted 2026-08-18; they are not a quote. Confirm the current itemized price and payment terms directly with the hospital before budgeting or travel.
Product drug price must not be confused with the total medical pathway cost. Complications, prolonged cytopenia, ICU care, and blood products will add to the final hospital bill.
Published intake contacts — confirm before use
needs direct confirmationThese numbers and addresses are published references captured 2026-08-18. They have not been reconfirmed for this case — call or email the hospital yourself to confirm the channel is still open, who answers, and what they need before you send records. Published intake references captured on the date shown. They were not re-confirmed by phone or email on this page, and individual hospitals can change or limit international patient channels.
Pre-Travel Clinical Intake Advisory
Treatment-specific eligibility, product availability, complication capacity, total pathway cost, and cross-border follow-up